The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma

Future Oncol. 2020 Dec;16(36):3017-3020. doi: 10.2217/fon-2020-0686. Epub 2020 Aug 28.
No abstract available

Keywords: Adrenocortical carcinoma; PD-L1; hypercortisolism; immune checkpoints inhibitors; immunogenicity; immunotherapy; progression-free survival; tumor infiltrating lymphocytes.

Publication types

  • Editorial
  • Historical Article

MeSH terms

  • Adrenal Cortex Neoplasms / drug therapy*
  • Adrenal Cortex Neoplasms / genetics
  • Adrenal Cortex Neoplasms / immunology
  • Adrenal Cortex Neoplasms / mortality
  • Adrenocortical Carcinoma / drug therapy*
  • Adrenocortical Carcinoma / genetics
  • Adrenocortical Carcinoma / immunology
  • Adrenocortical Carcinoma / mortality
  • Clinical Trials as Topic
  • Disease Progression
  • Drug Resistance, Neoplasm / genetics
  • Drug Resistance, Neoplasm / immunology
  • History, 21st Century
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Immunotherapy / history
  • Immunotherapy / methods*
  • Immunotherapy / trends
  • Progression-Free Survival

Substances

  • Immune Checkpoint Inhibitors